Beyond Platinum: Current Approaches to Advanced Bladder Cancer
There is an increasing focus on personalized treatment approaches in advanced and metastatic urothelial carcinoma (mUC). Recent advancements include biomarker-driven therapy selection, novel antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and targeted therapies. Managing treatment-related toxicities remains crucial, requiring interprofessional collaboration to monitor and mitigate adverse events. At JADPRO Live 2024, presenters discussed these considerations for advanced practitioners.
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Journal of the Advanced Practitioner in Oncology
- Published
- 2025-03-25
- DOI
- https://doi.org/10.6004/jadpro.2025.16.2.14
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00